Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.38 |
| ▸ | PPARG | P37231 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6423170 | 0.80 | ALDH1A1 (0.37) | EPHX2PPARGALDH1A1POLBCYP1A2 | |
| SCHEMBL2803839 | 0.77 | ALDH1A1 (0.39) | ALDH1A1POLBCYP1A2CYP2C9KMT2A | |
| SCHEMBL6420476 | 0.76 | HSD17B10 (0.43) | ALDH1A1POLBCYP1A2CYP2C9KMT2A | |
| SCHEMBL6418597 | 0.73 | EPHX2 (0.35) | EPHX2PPARGALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL2784963 | 0.73 | MMP1 (0.42) | ALDH1A1POLBCYP1A2CYP2C9KMT2A | |
| SCHEMBL6420432 | 0.70 | EPHX2 (0.41) | EPHX2PPARGALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL7795152 | 0.70 | KDM4E (0.34) | EPHX2ALDH1A1 | |
| SCHEMBL27750685 | 0.69 | ALDH1A1 (0.38) | ALDH1A1POLBKMT2A | |
| SCHEMBL7365956 | 0.69 | POLB (0.62) | EPHX2PPARGALDH1A1POLBKMT2A | |
| SCHEMBL6898655 | 0.69 | ALDH1A1 (0.37) | PPARGALDH1A1POLBCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010014737-A1 | Vitronectin receptor antagonist | HEERDING DIRK (US) | 2001-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014737-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | EPHX2 3480/4885PPARG 2307/4885ALDH1A1 3234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.